Spots Global Cancer Trial Database for Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
Official Title: Terapia Con Everolimus Nel Trapianto de Novo di Fegato: Uno Studio Multicentrico Randomizzato
Study ID: NCT01423708
Interventions
Study Description
Brief Summary: Safety and Efficacy of Everolimus in adult de novo liver transplant recipients.
Detailed Description: This prospective study was designed to evaluate the feasibility and effectiveness of the use of Everolimus in the minimization and possible suspension of calcineurin inhibitors in adult liver transplant patients. The study will take into account a control group (standard immunosuppression with tacrolimus and steroids) after induction with anti-IL2 Antibodies.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ospedali Riuniti - Bergamo, Bergamo, BG, Italy
Irccs Ospedale Maggiore Policlinico Di Milano, Milano, MI, Italy
Ospedale Ca' Granda-Niguarda - Milano, Milano, MI, Italy
Azienda Ospedaliera di Padova, Padua, PD, Italy
Policlinico Universitario Gemelli Di Roma, Roma, RM, Italy
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino, Torino, TO, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine, UD, Italy
Contact Details
Name: Umberto Cillo, MD
Affiliation: Azienda Ospedaliera di Padova
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
